JO3097B1 - الأجسام المضادة c-Met - Google Patents

الأجسام المضادة c-Met

Info

Publication number
JO3097B1
JO3097B1 JOP/2009/0424A JOP20090424A JO3097B1 JO 3097 B1 JO3097 B1 JO 3097B1 JO P20090424 A JOP20090424 A JO P20090424A JO 3097 B1 JO3097 B1 JO 3097B1
Authority
JO
Jordan
Prior art keywords
met
met antibodies
pathogenesis
antigen
mediated
Prior art date
Application number
JOP/2009/0424A
Other languages
English (en)
Inventor
Edward Vaillancourt Peter
Davis Julian
Lu Jirong
Liu Ling
Andrew Wortinger Mark
Zeng Wei
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3097B1 publication Critical patent/JO3097B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بأجسام مضادة أحادية النسيلة، وشظيات ربط مولد ضد منها، وتوليفات مما سبق، ترتبط بـ c-Met وتثبط نشاطه، وتتسم بأنها فعالة في علاج أنواع السرطان والأمراض أو الاضطرابات أو الحالات الأخرى التي يساهم c-Met في الإصابة بها.
JOP/2009/0424A 2008-11-21 2009-11-15 الأجسام المضادة c-Met JO3097B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682508P 2008-11-21 2008-11-21
US21990309P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
JO3097B1 true JO3097B1 (ar) 2017-03-15

Family

ID=41435259

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0424A JO3097B1 (ar) 2008-11-21 2009-11-15 الأجسام المضادة c-Met

Country Status (28)

Country Link
US (2) US8217148B2 (ar)
EP (2) EP2358755B1 (ar)
JP (1) JP5688027B2 (ar)
KR (1) KR101334450B1 (ar)
CN (1) CN102216333B (ar)
AR (1) AR074360A1 (ar)
AU (1) AU2009316742B2 (ar)
BR (1) BRPI0922800A2 (ar)
CA (1) CA2743508C (ar)
CY (1) CY1116886T1 (ar)
DK (1) DK2358755T3 (ar)
EA (1) EA020398B1 (ar)
ES (2) ES2663825T3 (ar)
HK (1) HK1158229A1 (ar)
HR (1) HRP20151019T1 (ar)
HU (1) HUE026058T2 (ar)
IL (1) IL212633A (ar)
JO (1) JO3097B1 (ar)
MX (1) MX2011005400A (ar)
NZ (1) NZ592215A (ar)
PA (1) PA8849001A1 (ar)
PL (1) PL2358755T3 (ar)
PT (1) PT2358755E (ar)
SI (1) SI2358755T1 (ar)
TR (1) TR201802841T4 (ar)
TW (1) TWI477284B (ar)
WO (1) WO2010059654A1 (ar)
ZA (1) ZA201103586B (ar)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
EP2576622A4 (en) * 2010-06-01 2013-11-27 Univ Monash ANTIBODIES AGAINST RECEPTOR TYROSINE KINASE C-MET
SG187886A1 (en) 2010-08-31 2013-04-30 Genentech Inc Biomarkers and methods of treatment
SG188324A1 (en) * 2010-09-03 2013-04-30 Academia Sinica Anti-c-met antibody and methods of use thereof
WO2012059562A1 (en) 2010-11-03 2012-05-10 Argen-X-Bv C-met antibody combinations
CN102276726B (zh) * 2011-03-16 2014-02-19 常州新泉生物医药科技有限公司 肝细胞生长因子受体活性基团的融合蛋白
US20140301989A1 (en) * 2011-06-17 2014-10-09 Brian Johnstone Methods for increasing the potency and efficacy of stem cells
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
WO2013043452A1 (en) * 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
RU2014124842A (ru) 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
CN104334581B (zh) * 2012-05-09 2018-02-02 伊莱利利公司 抗‑c‑Met抗体
CA2877573A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
EP2708556B1 (en) * 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
JP6491642B2 (ja) * 2013-04-30 2019-03-27 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ ｍＡｂ２抗Ｍｅｔ抗体
CA2917924A1 (en) * 2013-08-14 2015-02-19 Qiagen Mansfield, Inc. Compositions and methods for multimodal analysis of cmet nucleic acids
CN105899226B (zh) 2013-10-14 2020-05-12 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
CA2944717A1 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL250902B (en) * 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
US10344071B2 (en) 2015-07-28 2019-07-09 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
EP3909984A1 (en) 2015-11-03 2021-11-17 Merck Patent GmbH Affinity matured c-met antibodies
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
ES2896709T3 (es) * 2016-02-05 2022-02-25 Helixmith Co Ltd Anticuerpos anti-c-Met y usos de los mismos
GB2551372A (en) * 2016-06-16 2017-12-20 Bombardier Primove Gmbh A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer
JP2019527540A (ja) 2016-06-21 2019-10-03 ヤンセン バイオテツク，インコーポレーテツド システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
WO2018021188A1 (ja) * 2016-07-26 2018-02-01 学校法人日本大学 歯周炎治療薬及び歯周炎治療用組成物
US10439449B2 (en) 2016-08-10 2019-10-08 Microsoft Technology Licensing, Llc Coupling device modules for inductive data transmission
CA3036643C (en) * 2016-09-29 2021-10-26 Mitsubishi Tanabe Pharma Corporation Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
CA3037380A1 (en) * 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
SI3544634T1 (sl) 2016-11-23 2021-08-31 Eli Lilly And Company Konjugati zdravila s protitelesom proti met
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN106986932A (zh) * 2017-04-06 2017-07-28 海口市人民医院 一种c‑Met表位肽及其应用
EP3630844A4 (en) * 2017-05-30 2021-03-03 Chong Kun Dang Pharmaceutical Corp. NEW ANTI-C-MET ANTIBODY AND ITS USE
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１結合フィブロネクチンｉｉｉ型ドメイン
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
JP2024505577A (ja) * 2021-02-03 2024-02-06 ミシク セラピューティクス， インコーポレイテッド 抗体およびその使用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024515266A (ja) 2021-04-08 2024-04-08 ビョンディス・ビー．ブイ． 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0584125B1 (en) 1991-05-10 1997-07-16 PHARMACIA & UPJOHN S.p.A. Truncated forms of the hepatocyte growth factor (hgf) receptor
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
JP2008507252A (ja) 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
ZA200604864B (en) 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
CN102942631B (zh) * 2004-08-05 2015-03-25 健泰科生物技术公司 人源化抗c-met拮抗剂
RU2404193C2 (ru) 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта
MX2008009833A (es) 2006-02-06 2008-10-23 Metheresis Translational Res S Anticuerpo monoclonal anti-met, fragmentos y vectores del mismo para el tratamiento de tumores, y productos correspondientes.
AU2007220920B2 (en) * 2006-02-22 2012-08-02 Eli Lilly And Company Humanized anti-ghrelin antibodies
US8101727B2 (en) * 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2118318B1 (en) * 2007-02-08 2012-08-08 The Regents of the University of California Gnaq mutations in melanoma
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met

Also Published As

Publication number Publication date
JP2012509881A (ja) 2012-04-26
TWI477284B (zh) 2015-03-21
HK1158229A1 (en) 2012-07-13
PT2358755E (pt) 2015-11-12
EP2963058B1 (en) 2018-02-21
NZ592215A (en) 2012-09-28
EP2963058A1 (en) 2016-01-06
SI2358755T1 (sl) 2015-10-30
JP5688027B2 (ja) 2015-03-25
PL2358755T3 (pl) 2016-01-29
AU2009316742A1 (en) 2010-05-27
BRPI0922800A2 (pt) 2015-12-22
CN102216333B (zh) 2014-05-21
US8217148B2 (en) 2012-07-10
KR20110074612A (ko) 2011-06-30
DK2358755T3 (en) 2015-11-16
IL212633A0 (en) 2011-07-31
ES2549760T3 (es) 2015-11-02
AU2009316742B2 (en) 2012-06-07
IL212633A (en) 2015-03-31
CY1116886T1 (el) 2017-04-05
ES2663825T3 (es) 2018-04-17
US20100129369A1 (en) 2010-05-27
MX2011005400A (es) 2011-06-20
TW201023885A (en) 2010-07-01
CA2743508C (en) 2016-07-19
CN102216333A (zh) 2011-10-12
WO2010059654A1 (en) 2010-05-27
EA020398B1 (ru) 2014-10-30
EP2358755A1 (en) 2011-08-24
AR074360A1 (es) 2011-01-12
CA2743508A1 (en) 2010-05-27
US20120263723A1 (en) 2012-10-18
PA8849001A1 (es) 2010-06-28
US8398974B2 (en) 2013-03-19
HUE026058T2 (en) 2016-05-30
EA201170716A1 (ru) 2011-12-30
ZA201103586B (en) 2013-10-30
EP2358755B1 (en) 2015-09-02
TR201802841T4 (tr) 2018-03-21
HRP20151019T1 (hr) 2015-10-23
KR101334450B1 (ko) 2013-12-02

Similar Documents

Publication Publication Date Title
JO3097B1 (ar) الأجسام المضادة c-Met
UA103916C2 (en) Dkk-1 antibody
EA201200597A1 (ru) Моноклональные антитела к прогастрину и их применение
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
PH12017500864A1 (en) Anti-notch1 antibodies
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
WO2011143318A3 (en) Anti-fgfr2 antibodies
EA201370081A1 (ru) Антитела к cd48 и их применение
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
GB201109238D0 (en) Antibodies
MY158481A (en) Compositions and methods for treating inflammatory disorders
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
TN2015000277A1 (en) Bmp-6 antibodies
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
UA104739C2 (en) c-MET ANTIBODIES
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
UA112521C2 (uk) Антитіло проти gdf8 людини